BioSpecifics Technologies Corp

Type: Company
Name: BioSpecifics Technologies Corp
First reported 14 hours ago - Updated 12 hours ago - 2 reports

Update: BioSpecifics Announces Positive XIAFLEX Data For Cellulite

By Andy Batts :BioSpecifics Technologies (NASDAQ: BSTC ) recently announced positive, statistically significant results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum or CCH (known as XIAFLEX in the in the US and ... [Published BioPortfolio - 12 hours ago]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

BioSpecifics Technologies injects first patient in Phase II lipoma trial

BioSpecifics Technologies Corp., a biopharmaceutical company, has injected the first patient in its placebo-controlled Phase II clinical trial of XIAFLEX, or collagenase clostridium histolyticum, or CCH for the treatment of lipoma. The Company expects ... [Published Individual.com - Aug 25 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 7 reports

BioSpecifics’ Xiaflex demonstrates efficacy in Phase 2a cellulite study

BioSpecifics Technologies’ collagenase clostridium histolyticum showed promise for smoothing cellulite during a recent randomized, double-blind Phase 2a study in the US. ... [Published PBR - News - Aug 22 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Update: BioSpecifics Technologies Earnings

Summary BioSpecifics reported second quarter 2014 total revenue of $2.7 million, a decrease of 19% year-over-year. Net income came in at $0.6 million or $0.09 per basic share, compared to net income of $1.0 million or $0.16 per basic share in the year-ago ... [Published Seeking Alpha - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

BioSpecifics Technologies appoints new board member

BioSpecifics Technologies Corp., a biopharmaceutical company, has appointed Max Link to its board of directors, with a term of office expiring and to be renewed at the 2016 annual meeting of stockholders. BioSpecifics also announced that as of August ... [Published Individual.com - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the US and XIAPEX in the EU, has injected the first patient in its placebo-controlled ... [Published PharmaAsia - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 3 reports

BioSpecifics (BSTC) Q2 2014 Results - Earnings Call Transcript

OperatorGood day. And welcome to the BioSpecifics' Second Quarter Financial Results Conference Call and Webcast. All participants will be in listen-only mode. (Operator Instructions) After today’s presentation, there will be an opportunity to ask questions. ... [Published Seeking Alpha - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

BioSpecifics Tech misses by $0.04, misses on revenue

16:52 ET | About: BioSpecifics Technologies Corp. (BSTC)BioSpecifics Tech (NASDAQ:BSTC): Q2 EPS of $0.08 misses by $0.04.Revenue of $2.7M (-18.2% Y/Y) misses by $ ... [Published Seeking Alpha - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 09 2014 - 5 reports

BioSpecifics Technologies initiates phase II study of CCH for Lipoma

BioSpecifics Technologies , a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the E.U., has injected the first patient in its placebo-controlled ... [Published Center Watch - Aug 09 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Shift Towards Preventive Care Drives Demand for Foot Care Products, According to New Report by Global Industry Analysts, Inc.

(Date:8/5/2014)... The report "Enterprise Asset Management ... Field Service Management, Assets MRO) by Services (Implementation, ... and Analysis (2014-2019)" by MarketsandMarkets defines and segments ... an in-depth analysis and forecasting of market ... [Published Bio-Medicine - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 05 2014 - 5 reports

BioSpecifics Technologies Corp. Announces Appointment Of Max Link, Ph.D. To Board

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced the appointment of Max Link, Ph.D. to its Board of Directors, effective August 4, 2014, with a term of office ... [Published Benzinga.com - Aug 05 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

BioSpecifics Technologies Corp. to Be Added to Russell 3000® Index

LYNBROOK, N.Y., June 27, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced that effective ... [Published PR Newswire: Health - Jun 27 2014]

Quotes

...advance our pipeline and continue to uncover the vast potential of injectable collagenase," commented Thomas L Wegman, President of BioSpecifics. "Lipomas are common and affect 2% of the total human population. We hope to build upon the positive clinical data reported earlier this year, and to make progress toward potentially offering a nonsurgical therapy to patients with this condition."
"These positive results are very encouraging, particularly because both patients and physicians saw a statistically significant improvement in the appearance of cellulite after CCH treatment" commented Thomas L Wegman
...a statistically significant improvement in the appearance of cellulite after CCH treatment," commented Thomas L Wegman , President of BioSpecifics. "The market for cellulite treatment is large, which makes these data very exciting for the prospective commercial success of CCH in this indication. The results also position CCH as a potential treatment for other aesthetic needs, so we are eager to see continued progress by Auxilium in initiating a subsequent Phase 2b trial of CCH in cellulite in the second quarter of 2015."
...Thomas L Wegman, President of BioSpecifics, said, "This was a momentous quarter of milestones for XIAFLEX both commercially and clinically. We saw significant growth in revenues from XIAFLEX U S sales, most notably in Peyronie's disease. We are particularly pleased to see the number of vials shipped in the second quarter of 2014; 565 in April, 775 in May and then almost double that number in June with 1,412 vials shipped. This was a significant increase over the first quarter shipments of 598 vials."

More Content

All (48) | News (29) | Reports (0) | Blogs (16) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Update: BioSpecifics Announces Positive XIAFLEX... [Published BioPortfolio - 12 hours ago]
Update: BioSpecifics Announces Positive XIAFLEX... [Published Seeking Alpha - 14 hours ago]
BioSpecifics Technologies injects first patient... [Published Individual.com - Aug 25 2014]
BioSpecifics’ Xiaflex demonstrates efficacy in ... [Published PBR - News - Aug 22 2014]
BioSpecifics Technologies Corp announces positi... [Published Reuters - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published Bio-Medicine - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published TheStreet.com - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published Stock Nod - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published Reliance Trust - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire: Health - Aug 21 2014]
Update: BioSpecifics Technologies Earnings [Published Seeking Alpha - Aug 15 2014]
BioSpecifics Technologies appoints new board me... [Published Individual.com - Aug 14 2014]
BioSpecifics Technologies Corp. Announces Initi... [Published PharmaAsia - Aug 13 2014]
Frontrunning: August 12 [Published Zero Hedge - Aug 12 2014]
Oncothyreon acquires Alpine Biosciences to enab... [Published News-Medical.Net - Aug 12 2014]
BioSpecifics (BSTC) Q2 2014 Results - Earnings ... [Published Seeking Alpha - Aug 12 2014]
BioSpecifics Tech misses by $0.04, misses on re... [Published Seeking Alpha - Aug 11 2014]
BioSpecifics Technologies Corp. Reports Second ... [Published TickerTech.com - Aug 11 2014]
BioSpecifics Technologies Corp. Reports Second ... [Published PR Newswire: Financial Services - Aug 11 2014]
MOH Opens Wallet, TNXP On The Move, Court Favor... [Published RTTNews.com - Aug 11 2014]
BioSpecifics Technologies initiates phase II st... [Published Center Watch - Aug 09 2014]
Ex-Sanofi exec Whitaker takes the reins at Synta [Published FierceBiotech - Aug 08 2014]
BioSpecifics Technologies Corp. Announces Initi... [Published Bio-Medicine - Aug 08 2014]
BioSpecifics Technologies Corp. Announces Initi... [Published Pettinga Financial Advisors - Aug 08 2014]
BioSpecifics Technologies Corp. Announces Initi... [Published TickerTech.com - Aug 08 2014]
BioSpecifics Technologies Corp. Announces Initi... [Published PR Newswire: Health - Aug 08 2014]
Shift Towards Preventive Care Drives Demand for... [Published Bio-Medicine - Aug 05 2014]
BioSpecifics Technologies Corp. Announces Appoi... [Published Benzinga.com - Aug 05 2014]
BioSpecifics Technologies Corp. Announces Appoi... [Published Barchart - Aug 05 2014]
BioSpecifics Technologies Corp. Announces Appoi... [Published Financial Services - Aug 05 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BioSpecifics’ Xiaflex demonstrates efficacy in ... [Published PBR - News - Aug 22 2014]
BioSpecifics Technologies’ collagenase clostridium histolyticum showed promise for smoothing cellulite during a recent randomized, double-blind Phase 2a study in the US. ...
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire: Health - Aug 21 2014]
LYNBROOK, N.Y., Aug. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ...
Frontrunning: August 12 [Published Zero Hedge - Aug 12 2014]
Gunshots, tear gas in riots over shooting of black Missouri teen ( Reuters ) Russia sends big aid convoy to Ukraine, West sounds warnings ( Reuters ) Maliki Bid to Block Successor Escalates Crisis in Iraq ( BBG ) Poor German data pushes euro toward 9-month ...
BioSpecifics Technologies Corp. Reports Second ... [Published PR Newswire: Financial Services - Aug 11 2014]
LYNBROOK, N.Y., Aug. 11, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ...
BioSpecifics Technologies Corp. Announces Initi... [Published PR Newswire: Health - Aug 08 2014]
LYNBROOK, N.Y., Aug. 8, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ...
1 2 3 4

Press Releases

sort by: Date | Relevance
BioSpecifics Technologies Corp. Announces Appoi... [Published Financial Services - Aug 05 2014]
BioSpecifics Technologies Corp (NASDAQ: BSTC) t... [Published GlobeNewswire: Advertising News - Jul 22 2014]
BioSpecifics Technologies Corp. Reports Fourth ... [Published Financial Services - Mar 06 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.